Schuster, SJ, Bishop MR, Tam C, et al. Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) – an interim analysis. EHA 2017, LBA2604.
Rituximab-monotherapie versus afwachtend beleid bij gevorderd, asymptomatisch FL
aug 2025 | Lymfoom